Drugs / APC-100
APC-100
also known as
2,2,5,7,8-Pentamethyl-6 · 2,2,5,7,8-Pentamethyl-6-chromanol · 2,2,5,7,9-pentamethyl-6-chromanol · Chromane c1 · NSC-226236 · Pentamethylchromanol
Small molecule targets AR via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01436214 | Aug 2011 → Aug 2016 | prostate cancer | Adamis Pharmaceuticals Corporation | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APC-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01436214 ↗ |
| Known as | 2,2,5,7,8-Pentamethyl-6 | “Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer” NCT01436214 ↗ |
| Known as | 2,2,5,7,8-Pentamethyl-6-chromanol | “This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.” NCT01436214 ↗ |
| Known as | 2,2,5,7,9-pentamethyl-6-chromanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL37676 ↗ |
| Known as | Chromane c1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL37676 ↗ |
| Known as | NSC-226236 | ChEMBL registry synonym — accepted as the source's own label CHEMBL37676 ↗ |
| Known as | Pentamethylchromanol | “Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer” NCT01436214 ↗ |
| Action | Inhibit | “Androgen Receptor antagonist” CHEMBL37676 ↗ |
| Modality | Small molecule | — CHEMBL37676 ↗ |
| Route | Oral | “Daily oral, dose escalation, 28-day cycle(s)” NCT01436214 ↗ |
| Target | AR | “Androgen Receptor antagonist” CHEMBL37676 ↗ |